Table 2.
Without Propensity Match | With Propensity Match | |||
---|---|---|---|---|
Hazard of Death (95% CI) | P Value | Hazard of Death (95% CI) | P Value | |
Pelvic radiotherapy | ||||
Surgery alone | Reference | |||
Surgery + XRT | 0.72 (0.66–0.78) | < .001 | 0.72 (0.67–0.78) | < .001 |
Gender | ||||
Male | Reference | |||
Female | 1.35 (1.23–1.48) | < .001 | ||
Age, y | ||||
≤ 65 | Reference | |||
> 65 | 1.35 (1.23–1.48) | < .001 | ||
Insurance | ||||
Insured | Reference | |||
Uninsured | 1.07 (0.90–1.28) | .445 | 1.08 (0.90–1.28) | .430 |
Income, $ | ||||
< 48,000 | Reference | |||
≥ 48,000 | 1.11 (1.03–1.21) | .008 | 1.10 (1.01–1.19) | .022 |
Facility | ||||
Community | Reference | |||
Academic | 0.80 (0.73–0.87) | < .001 | 0.78 (0.72–0.85) | < .001 |
Population | ||||
Metro/urban | Reference | |||
Rural | 1.08 (0.90–1.28) | .445 | 1.13 (0.96–1.33) | .159 |
Comorbidity score | ||||
0 | Reference | |||
≥ 1 | 0.94 (0.84–1.04) | .216 | 0.95 (0.85–1.05) | .316 |
Clinical T stage | ||||
T1/T2 | Reference | |||
T3/T4 | 0.80 (0.88–1.18) | .803 | ||
Unknown | 0.92 (0.96–1.30) | .14 | ||
Clinical N stage | ||||
N0 | Reference | |||
N1 | 0.93 (0.84–1.03) | .803 | ||
N2 | 1.36 (1.20–1.54) | .14 | ||
Unknown | 1.18 (1.05–1.32) | .007 | ||
Grade | ||||
1–2 | Reference | |||
3 | 1.51 (1.37–1.67) | < .001 | ||
Metastatic burden | ||||
1 organ involved | Reference | |||
Multiple organs involved | 0.74 (0.67–0.80) | < .001 | 0.73 (0.67–0.79) | < .001 |
Abbreviations: CI = confidence interval; XRT = pelvic radiotherapy.